Skip main navigation

Complications of ESRD : renal osteodystrophy and anemia

Complications of ESRD : renal osteodystrophy and anemia

In this step, Prof. Chen introduces phosphate binder magnesium containing products and other complications for patients in chronic kidney failure.

Phosphate binder magnesium containing products have the highest binding potency. However, they are associated with direct toxicity to bone (osteomalacia), microcytic anemia, dialysis encephalopathy, and fatal neurologic syndrome.

Therefore, they should be reserved for severe hyperphosphatemia with high serum calcium, or for short term use for acute phase.

When providing calcium supplement as a treatment to hypocalcemia, we need to calculate a calcium and phosphorus label to avoid causing those accumulations.

For renal osteodystrophy, we need to learn the symptoms, goals, and the treatments. Besides, we still need to consider aluminum toxicity and PTH problem.

Ultimately, anemia is a common complication in chronic kidney failure. Due to decreased erythropoietin (EPO) production, the main treatments only have transfusion, EPO therapy, and iron therapy.

This article is from the free online

Pharmacokinetics: Drug Dosing in Renal Disease

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now